Vertex Pharmaceuticals Return On Asset Trend

VRTX -- USA Stock  

Fiscal Quarter End: December 31, 2019  

This module enables investors to look at Vertex Pharmaceuticals various fundamental indicators over time in order to gain insight into the company future performance. Macroaxis historical fundamental analysis tools allow evaluation of not only typical financial statement drivers such as Direct Expenses of 291.1 M, Cost of Revenue of 125.5 M or Gross Profit of 1.2 B, but also many exotic indicators such as Interest Coverage of 11.8293, Long Term Debt to Equity of 0.354 or PPandE Turnover of 4.1348. This module is a perfect complement to use when analyzing Vertex Pharmaceuticals Valuation or Volatility. It can also complement various Vertex Pharmaceuticals Technical models. Also please take a look at analysis of Vertex Pharmaceuticals Correlation with competitors.

Vertex Pharmaceuticals Return On Asset Marginal Breakdown

Showing smoothed Return on Average Assets of Vertex Pharmaceuticals Incorpor with missing and latest data points interpolated. Return on assets measures how profitable a company is [NetIncCmn] relative to its total assets [AssetsAvg].
View

8.30 

          10 Years Trend
 Return on Average Assets 
      Timeline 

Vertex Pharmaceuticals Regression Statistics

Arithmetic Mean(10.26)
Coefficient Of Variation(242.98)
Mean Deviation 19.22
Median(4.31)
Standard Deviation 24.94
Sample Variance 621.99
Range 86.57
R Value 0.69
Mean Square Error 363.71
R Squared 0.47
Significance 0.019205
Slope 5.18
Total Sum of Squares 6,220

Vertex Pharmaceuticals Return On Asset Over Time

2017  8.18 
2018  42.83 
2019  0.08 

Other Fundumenentals of Vertex Pharmaceuticals

Search macroaxis.com